公开(公告)号：US09889149B2

公开(公告)日：2018-02-13

申请号：US13941625

申请日：2013-07-15

Applicant: N.V. Nutricia

Inventor： Robert Johan Joseph Hageman

IPC: A61K31/714 ,  A61K31/198 ,  A61K31/4188 ,  A61K36/48 ,  A61K36/81 ,  A61K36/899 ,  A61K38/01 ,  A23L13/60 ,  A23L23/10 ,  A23L33/17 ,  A23L33/175 ,  A23L33/18 ,  A23L33/185 ,  A23L33/19 ,  A61K38/02 ,  A23L33/00 ,  A23L13/40

CPC classification number: A61K31/714 ,  A23L13/424 ,  A23L13/65 ,  A23L23/10 ,  A23L33/17 ,  A23L33/175 ,  A23L33/18 ,  A23L33/185 ,  A23L33/19 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/198 ,  A61K31/4188 ,  A61K36/48 ,  A61K36/81 ,  A61K36/899 ,  A61K38/01 ,  A61K38/02 ,  A61K2300/00 ,  A23V2200/328 ,  A23V2250/0636 ,  A23V2250/061 ,  A23V2250/0628 ,  A23V2250/062 ,  A23V2250/5114 ,  A23V2250/608 ,  A23V2250/61 ,  A23V2250/1882 ,  A23V2250/5106 ,  A23V2250/156 ,  A23V2250/15 ,  A23V2200/332 ,  A23V2250/0618 ,  A23V2250/54252 ,  A23V2250/5488 ,  A23V2250/612 ,  A23V2250/1842 ,  A23V2250/702 ,  A23V2250/712 ,  A23V2250/7042 ,  A23V2250/7052 ,  A23V2250/72 ,  A23V2250/7046 ,  A23V2250/0644 ,  A23V2250/1614 ,  A23V2250/1618 ,  A23V2250/1582 ,  A23V2250/1592 ,  A23V2250/1588

Abstract: The invention relates to the use of specific protein and/or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. The invention relates to a complete food fortified with aspartate equivalents as well as a supplement rich in aspartate equivalents that is given simultaneously with or even minutes up to an hour prior to the consumption of a meal comprising glucose. The nutritional or pharmaceutical composition contains at least one protein having a high aspartate content, preferably of soy or dairy origin, which is further enriched with aspartate equivalents from another protein and/or free aspartate equivalents. The protein fraction comprises glutamate equivalents in a weight ratio of aspartate equivalents to glutamate equivalents (asp:glu) between 0.41:1 and 5:1.

公开(公告)号：US20150272982A1

公开(公告)日：2015-10-01

申请号：US14412782

申请日：2013-07-05

Applicant: N.V. Nutricia

Inventor： Robert Johan Joseph Hageman

IPC: A61K31/717 ,  A61K38/08 ,  A23L1/30 ,  A23L1/308 ,  A23L1/305 ,  A61K31/405 ,  A61K31/202

CPC classification number: A61K31/717 ,  A23L33/10 ,  A23L33/175 ,  A23L33/18 ,  A23L33/21 ,  A23L33/22 ,  A23L33/24 ,  A23L33/30 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/138 ,  A61K31/202 ,  A61K31/343 ,  A61K31/405 ,  A61K31/716 ,  A61K31/718 ,  A61K36/899 ,  A61K38/08 ,  A23V2200/3202 ,  A23V2200/322 ,  A23V2250/0624 ,  A23V2250/063 ,  A23V2250/0648 ,  A23V2250/548 ,  A23V2250/70 ,  A23V2250/065 ,  A23V2250/156 ,  A23V2250/161 ,  A23V2250/1846 ,  A23V2250/1882 ,  A23V2250/5034 ,  A23V2250/5062 ,  A23V2250/54 ,  A61K2300/00

Abstract: The invention relates to a nutritional composition comprising dietary fibre, a peptide having 7 or more amino acid units, the nutritional composition comprising a tryptophan source, which may be said peptide or different there from, for use in the treatment of a negative emotion or introvert behaviour. The invention further relates to a combination of dietary fibre, a peptide having 7 or more amino acid units, the nutritional composition comprising a tryptophan source, which may be said peptide or different there from, and optionally one or more other components, for use in the treatment of a negative emotion or introvert behaviour.

Abstract translation: 本发明涉及一种营养组合物，其包含膳食纤维，具有7个或更多个氨基酸单元的肽，所述营养组合物包含色氨酸来源，其可以是所述肽或不同于用于治疗阴性情绪或内向的肽 行为。 本发明还涉及膳食纤维，具有7个或更多个氨基酸单元的肽的组合，所述营养组合物包含色氨酸来源，所述色氨酸来源可以是所述肽或与其不同的肽，以及任选的一种或多种其它成分，用于 治疗消极情绪或内向行为。

公开(公告)号：US09539278B2

公开(公告)日：2017-01-10

申请号：US14516129

申请日：2014-10-16

Applicant: N.V. Nutricia

Inventor： Robert Johan Joseph Hageman

IPC: A61K31/4188 ,  A61K31/714 ,  A61K36/48 ,  A61K36/81 ,  A61K36/899 ,  A61K38/01 ,  A61K38/02 ,  A61K31/198

CPC classification number: A61K31/714 ,  A23L13/424 ,  A23L13/65 ,  A23L23/10 ,  A23L33/17 ,  A23L33/175 ,  A23L33/18 ,  A23L33/185 ,  A23L33/19 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/198 ,  A61K31/4188 ,  A61K36/48 ,  A61K36/81 ,  A61K36/899 ,  A61K38/01 ,  A61K38/02 ,  A61K2300/00 ,  A23V2200/328 ,  A23V2250/0636 ,  A23V2250/061 ,  A23V2250/0628 ,  A23V2250/062 ,  A23V2250/5114 ,  A23V2250/608 ,  A23V2250/61 ,  A23V2250/1882 ,  A23V2250/5106 ,  A23V2250/156 ,  A23V2250/15 ,  A23V2200/332 ,  A23V2250/0618 ,  A23V2250/54252 ,  A23V2250/5488 ,  A23V2250/612 ,  A23V2250/1842 ,  A23V2250/702 ,  A23V2250/712 ,  A23V2250/7042 ,  A23V2250/7052 ,  A23V2250/72 ,  A23V2250/7046 ,  A23V2250/0644 ,  A23V2250/1614 ,  A23V2250/1618 ,  A23V2250/1582 ,  A23V2250/1592 ,  A23V2250/1588

Abstract: It has been found that high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, especially in relative absence of glutamate equivalents, improve the metabolism of ketobodies and/or lactate in a mammal's body, especially in diseased or traumatic conditions. As a result, levels of ketobodies and lactate can be decreased and unphysicologically high acidity normalised. Thus, it is an object of the invention to provide an enteral nutritional or a pharmaceutical composition for the treatment and/or prevention of disturbed ketone and lactate metabolism, i.e. elevated concentrations of ketone bodies, lactate and/or other organic acids and/or insufficient pH homeostasis, especially elevated concentrations of ketone bodies and/or lactate, in a mammal's blood, wherein the composition comprises high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, preferably in relative absence of glutamate equivalents.

Abstract translation: 已经发现，大量天冬氨酸当量与维生素B12和/或生物素组合，特别是相对不存在谷氨酸当量时，改善了哺乳动物身体中酮体和/或乳酸盐的代谢，特别是在患病或创伤性病症中。 结果，可以降低酮体和乳酸盐的水平，并且在非物理学上较高的酸度归一化。 因此，本发明的目的是提供用于治疗和/或预防受损的酮和乳酸代谢的肠内营养或药物组合物，即酮体，乳酸盐和/或其它有机酸的浓度升高和/或不足 pH稳定，特别是哺乳动物血液中酮体和/或乳酸浓度升高，其中组合物包含与维生素B12和/或生物素组合的大量天冬氨酸当量，优选相对不存在谷氨酸当量。

公开(公告)号：US20140161928A1

公开(公告)日：2014-06-12

申请号：US13941625

申请日：2013-07-15

Applicant: N.V. Nutricia

Inventor： Robert Johan Joseph Hageman

IPC: A23L1/305

CPC classification number: A61K31/714 ,  A23L13/424 ,  A23L13/65 ,  A23L23/10 ,  A23L33/17 ,  A23L33/175 ,  A23L33/18 ,  A23L33/185 ,  A23L33/19 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/198 ,  A61K31/4188 ,  A61K36/48 ,  A61K36/81 ,  A61K36/899 ,  A61K38/01 ,  A61K38/02 ,  A61K2300/00 ,  A23V2200/328 ,  A23V2250/0636 ,  A23V2250/061 ,  A23V2250/0628 ,  A23V2250/062 ,  A23V2250/5114 ,  A23V2250/608 ,  A23V2250/61 ,  A23V2250/1882 ,  A23V2250/5106 ,  A23V2250/156 ,  A23V2250/15 ,  A23V2200/332 ,  A23V2250/0618 ,  A23V2250/54252 ,  A23V2250/5488 ,  A23V2250/612 ,  A23V2250/1842 ,  A23V2250/702 ,  A23V2250/712 ,  A23V2250/7042 ,  A23V2250/7052 ,  A23V2250/72 ,  A23V2250/7046 ,  A23V2250/0644 ,  A23V2250/1614 ,  A23V2250/1618 ,  A23V2250/1582 ,  A23V2250/1592 ,  A23V2250/1588

Abstract: The invention relates to the use of specific protein and/or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. The invention relates to a complete food fortified with aspartate equivalents as well as a supplement rich in aspartate equivalents that is given simultaneously with or even minutes up to an hour prior to the consumption of a meal comprising glucose. The nutritional or pharmaceutical composition contains at least one protein having a high aspartate content, preferably of soy or dairy origin, which is further enriched with aspartate equivalents from another protein and/or free aspartate equivalents. The protein fraction comprises glutamate equivalents in a weight ratio of aspartate equivalents to glutamate equivalents (asp:glu) between 0.41:1 and 5:1.

Abstract translation: 本发明涉及具有高天冬氨酸含量的特定蛋白质和/或肽级分用于调节哺乳动物血浆葡萄糖浓度和增加胰岛素敏感性的用途。 本发明涉及用天冬氨酸当量加强的完整食物以及富含天冬氨酸当量的补充剂，其在消耗包含葡萄糖的膳食之前同时或甚至数分钟至少一小时。 营养或药物组合物含有至少一种具有高天冬氨酸含量，优选大豆或乳制品来源的蛋白质，其进一步富含来自另一蛋白质和/或游离天冬氨酸当量的天冬氨酸当量。 蛋白质级分包含谷氨酸当量，天门冬氨酸当量与谷氨酸当量（asp：glu）的重量比在0.41:1和5:1之间。

公开(公告)号：US11707478B2

公开(公告)日：2023-07-25

申请号：US16327741

申请日：2017-08-23

Applicant: N.V. Nutricia

Inventor： Robert Johan Joseph Hageman

IPC: A61K31/7072 ,  A61K9/08 ,  A61K47/12 ,  A61K9/00 ,  A61K33/14 ,  A61K45/06 ,  A61P7/00 ,  A61K31/14 ,  A61K31/202 ,  A61K31/519 ,  A61K31/675 ,  A61K31/7105 ,  A61K33/00

CPC classification number: A61K31/7072 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/08 ,  A61K31/14 ,  A61K31/202 ,  A61K31/519 ,  A61K31/675 ,  A61K31/7105 ,  A61K33/00 ,  A61K33/14 ,  A61K45/06 ,  A61K47/12 ,  A61P7/00 ,  A61K31/7072 ,  A61K2300/00 ,  A61K33/14 ,  A61K2300/00

Abstract: The invention pertains to the use of soluble sodium in the manufacture of a composition or kit of parts for (therapeutically) improving and prolonging blood plasma uridine levels and tissue availability of uridine, and/or for treating or preventing impaired blood plasma uridine levels and tissue availability of uridine, and/or for preventing/treating disorders associated with impaired blood plasma and tissue availability of uridine, in a mammal, preferably a human being, by orally co-administering soluble sodium and uridine in a molar ratio of soluble sodium to uridine of more than 1:1, preferably more than 1.5:1, more preferably more than 2:1, even more preferably at least 2.5:1, even more preferably at least 2.8:1, more preferably 3:1-15:1, most preferably 3:1-10:1, particularly 3:1-5:1.

公开(公告)号：US20200261488A1

公开(公告)日：2020-08-20

申请号：US16739663

申请日：2020-01-10

Applicant: N.V. Nutricia

Inventor： Mattheus Cornelis De Wilde ,  Robert Johan Joseph Hageman

IPC: A61K31/7072 ,  A61K31/202 ,  A61K31/133 ,  A61K31/4415 ,  A61K31/714 ,  A61K31/375 ,  A61K31/355 ,  A61K9/20 ,  A61K9/00 ,  A61K9/48

Abstract: The invention pertains to a composition for use in producing white matter, producing myelin and/or reducing brain lesion size in a mammal suffering from or recovering from traumatic brain injury, comprising enterally administering to the subject a composition comprising therapeutically effective amounts of: (i) one or more of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof; (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), preferably at least DHA, more preferably DHA and EPA, wherein the lipid fraction comprises less than 2 weight % of α-linolenic acid (ALA), calculated on the weight of all fatty acids; (iii) choline, or salts or esters thereof; and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.

公开(公告)号：US20200146326A1

公开(公告)日：2020-05-14

申请号：US16739601

申请日：2020-01-10

Applicant: N.V. Nutricia

Inventor： Robert Johan Joseph Hageman ,  Ladislaus Maria Broersen ,  Nick Van Wijk

IPC: A23L33/115 ,  A23L33/17 ,  A23L33/125

Abstract: The invention provides for an enteral nutritional composition comprising (a) a lipid fraction, (b) a digestible carbohydrate fraction and (c) a protein fraction, wherein the lipid fraction comprises therapeutically effective amounts of (i) DHA and optionally EPA, and (ii) medium-chain triglycerides, preferably at least 2 wt % C8 and C10 medium-chain triglycerides based on weight of the fatty acids; and wherein the composition has a ketogenic weight ratio between 1.4:1 and 3:1, for use in the treatment of traumatic brain injury (TBI).

公开(公告)号：US09844525B2

公开(公告)日：2017-12-19

申请号：US15338751

申请日：2016-10-31

Applicant: N.V. Nutricia

Inventor： Amanda Johanne Kiliaan ,  Robert Johan Joseph Hageman

IPC: A61K8/67 ,  A61K8/92 ,  A61K31/202 ,  A61K31/14 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/714 ,  A61K33/06 ,  A61K33/30 ,  A61K45/06 ,  A61K31/685 ,  A61K47/22 ,  A61K47/26

CPC classification number: A61K31/202 ,  A61K31/14 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/685 ,  A61K31/714 ,  A61K33/06 ,  A61K33/30 ,  A61K45/06 ,  A61K47/22 ,  A61K47/26 ,  Y10S514/904 ,  A61K2300/00

Abstract: The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B 12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD.

公开(公告)号：US09504712B2

公开(公告)日：2016-11-29

申请号：US14634368

申请日：2015-02-27

Applicant: N.V. Nutricia

Inventor： Amanda Johanne Kiliaan ,  Robert Johan Joseph Hageman

IPC: A61K31/14 ,  A61K31/202 ,  A61K31/519 ,  A61K31/714 ,  A61K33/06 ,  A61K33/30 ,  A61K45/06 ,  A61K31/4415

CPC classification number: A61K31/202 ,  A61K31/14 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/685 ,  A61K31/714 ,  A61K33/06 ,  A61K33/30 ,  A61K45/06 ,  A61K47/22 ,  A61K47/26 ,  Y10S514/904 ,  A61K2300/00

Abstract: The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD.

Abstract translation: 该制剂有利地应用于患有帕金森病，亨廷顿舞蹈症，癫痫，精神分裂症，偏执狂，抑郁症，睡眠障碍，记忆障碍受损，精神病，痴呆和ADHD的患者。

公开(公告)号：US20150164945A1

公开(公告)日：2015-06-18

申请号：US14634368

申请日：2015-02-27

Applicant: N.V. Nutricia

Inventor： Amanda Johanne KILIAAN ,  Robert Johan Joseph Hageman

IPC: A61K33/30 ,  A61K33/06 ,  A61K31/4415 ,  A61K31/714 ,  A61K31/202 ,  A61K31/519

CPC classification number: A61K31/202 ,  A61K31/14 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/685 ,  A61K31/714 ,  A61K33/06 ,  A61K33/30 ,  A61K45/06 ,  A61K47/22 ,  A61K47/26 ,  Y10S514/904 ,  A61K2300/00

Abstract: The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD.

Abstract translation: 本发明涉及多不饱和脂肪酸和一种或多种对维生素B12及其前体，维生素B6及其衍生物，叶酸，锌和镁等维生素B12及其衍生物有选择性的总甲硫氨酸代谢有益作用的成分， 在制备改善受体作用的制剂中。 该制剂有利地应用于患有帕金森病，亨廷顿舞蹈症，癫痫，精神分裂症，偏执狂，抑郁症，睡眠障碍，记忆障碍受损，精神病，痴呆和ADHD的患者。